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Lack of dystrophin results in skeletal muscle dystrophy and dilated cardiomyopathy in humans and animal models. To achieve a basic
understanding of the natural development of cardiomyopathy in diﬀerent dystrophinopathy mouse models, left and right ventricular
heart function was assessed at diﬀerent ages in three dystrophinopathy mouse models (mdx, mdx/utrn+/ model and mdx/utrn/) using
magnetic resonance imaging. Left ventricular function was signiﬁcantly decreased, already at 2 months in the most severely aﬀected mdx/
utrn/ mice. Furthermore, whereas heart function was stable in wild-type mice over time, both mdx and mdx/utrn+/ showed a clear
decrease at 10 months of age, most prominently in the right ventricle. Therefore magnetic resonance imaging is an adequate technique to
determine heart function in dystrophinopathy mouse models and can be used to assess the eﬀect of potential therapies.
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Duchenne muscular dystrophy (DMD) is a severe, pro-
gressive muscle wasting disorder that aﬀects around 1 in
3500 newborn boys [1]. It is caused by a genetic defect in
the DMD gene located on the X-chromosome (Xp21),
encoding the dystrophin protein. Frame-shifting mutations
or premature stop codons cause the loss of functional dys-
trophin [2]. Dystrophin is located inside the muscle ﬁbres
and is part of the dystrophin-associated protein complex
(DAPC), which has an important role in providing0960-8966  2011 Elsevier B.V.
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contraction [3].
Symptoms in DMD patients generally start before the
age of six and involve weakness of the lower extremities
muscles leading to loss of ambulation around the age of
10–15. Involvement of the diaphragm causes the need of
assisted ventilation in the late teens [4]. Most of the patients
also exhibit clinically relevant cardiac involvement. Elec-
trocardiogram (ECG) abnormalities, depressed left ventric-
ular function and a dilated left ventricle are found in >95%
of patients [5,6]. Most patients stay asymptomatic till late
stages of heart failure, probably due to lack of physical
activity, but dilated cardiomyopathy eventually causes
death in 10–20% of patients, and is becoming more impor-
tant due to improvements in clinical care [7–9].
Several mouse models exist for dystrophinopathy [10].
The most common model is the mdx (C57Bl/10ScSn-
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codon in exon 23, leading to the production of a truncated,
non-functional dystrophin protein [11]. However, due to a
better muscle regenerative capacity and upregulation of the
dystrophin homologue utrophin, mice have only a mild
phenotype compared to humans, and have only a slightly
shorter life expectancy compared to wild-type mice [12].
Nevertheless, muscle function is impaired and muscles
exhibit a dystrophic phenotype. A more severely aﬀected
mouse model is the mdx/utrn/ mouse, lacking both dys-
trophin and utrophin. The severe phenotype of these mice
is more comparable to humans and these mice have an
average life expectancy of around 2–3 months [13]. This
very short life span makes it diﬃcult to use these animals
for study purposes. Heterozygote mice with one functional
utrophin copy (mdx/utrn+/ mice) exhibit an intermediate
phenotype. Muscle inﬂammation and ﬁbrosis is worse com-
pared to mdx mice, but life span is longer than that of mdx/
utrn/ mice [14]. Although the phenotype of mdx/utrn+/
and mdx/utrn/ mice is more comparable to humans, a
disadvantage of these mice is the heterogeneity in the back-
ground of these mice [15], which causes larger variations
between individual mice.
Although some studies have been performed to assess
heart function in mouse models for DMD, they mainly
used mdx mice and the results are sometimes inconsistent.
In young mdx mice no diﬀerences in cardiac function are
found when compared to age-matched wild-type mice.
Dilated cardiac myopathy starts to develop when mice
are ageing, becoming prominent at 9–10 months of age
when changes in functional parameters (e.g. decrease of
shortening fraction) are found using electrocardiography
(ECG) or echocardiography [16–19]. In contrast, Li
et al. did not observe this functional decline by ECG even
in 10 months old mice, and only found alterations with
more sensitive methods (cardiovascular magnetic reso-
nance tagging) [20]. Furthermore, some studies describe
an increase in left ventricular internal diameter (end sys-
tolic and/or end diastolic) [17,19]. In addition, around
the age of 6 months ﬁnding on cardiac perfomance vary
from virtually no decline in mdx mice [17] to some [16]
or even prominent deterioration in cardiac function [21].
This may be because most studies use only ECG analysis,
which is a global method to determine cardiac function,
using geometric assumptions for the calculation of func-
tional parameters. This technique is therefore less suitable
to detect changes in ventricular shape. Magnetic reso-
nance imaging (MRI) has been shown to be a more sen-
sitive and accurate technique for high resolution imaging
and determination of ventricular function, both in nor-
mally shaped hearts and in hearts deformed by diseases
[22–24].
Knowledge about cardiac involvement in dystrophinop-
athy mouse models is important to assess their validity as
disease models, since cardiomyopathy is a prominent fea-
ture in DMD patients. Furthermore, a basic understandingof good biomarkers for heart pathology is needed to be
able to monitor therapeutic eﬀects of potential treatments
in animal models on the heart muscle.
Therefore, the aim of this study is to compare the car-
diac involvement of diﬀerent mouse models for DMD
and the development of cardiomyopathy in these mouse
models over time using cine-MRI with retrospective
ECG-gating.2. Materials and methods
2.1. Animals
C57Bl/10ScSnJ, mdx (C57Bl/10ScSn-DMDmdx/J), mdx/
utrn+/ and mdx/utrn/ were obtained from our own
breeding facilities. All experiments were approved by the
animal ethical experimental committee of the Leiden Uni-
versity Medical Center (LUMC) (project 09185). Mice
were housed in individually ventilated cages in the animal
facility of the LUMC and transported to the animal facility
of the Faculty of Science of the University of Leiden 7 days
before analysis for acclimatisation. Mice received food and
drink ad libitum.
The four diﬀerent genotypes were assessed in a cross-
sectional design: wild-type (C57Bl/10ScSnJ, mdx (C57Bl/
10ScSn-DMDmdx/J), and mdx/utrn+/ mice were analysed
at 2, 6 and 10 months of age (n = 6 per time-point) and
mdx/utrn/ at 2 months of age (n = 6). Each group con-
sisted of 3 male and 3 female mice. Mice were anaesthe-
tized by inhalation of 2% isoﬂurane in 1:1 oxygen:air.
Respiration rate was monitored with a respiratory pad
and kept constant at 50–80 respirations per minute dur-
ing the MRI scan. After the analysis, anaesthetized mice
were sacriﬁced by cervical dislocation. Hearts were iso-
lated and snap frozen in liquid nitrogen-cooled 2-methyl-
butane (Sigma–Aldrich, The Netherlands).2.2. MRI
Mice were imaged using a vertical 9.4 T magnet with
89 mm bore size, equipped with a 1 T/m gradient system
(Bruker BioSpin, Germany) using a quadrature birdcage
coil with an inner diameter of 30 mm.
Bruker Paravision 5.0 software was used for image
acquisition. A self-gated cine MRI sequence was used
(Intragate) based on a navigator-based retrospective gating
technique, followed by sorting data points according to
their origin in the cardiac cycle [25]. Imaging parameters
were with ﬂip angle 10; repetition time 8.5 ms; echo time
1.86 ms; ﬁeld-of-view 2.56  2.56 cm2; matrix 192  192;
in-plane resolution 133 lm; slice thickness 1 mm; 8–9
short-axis slices, number of repetitions 200; total acquisi-
tion time approximately 30 min. The navigator echo was
placed in-slice. Images were reconstructed to 18 frames
per heart cycle.
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Images were analysed with MASS for mice software
(developed in-house at the LUMC, Division of Image Pro-
cessing (LKEB)) [26,27]. Endocardial and epicardial con-
tours were drawn manually for both left and right
ventricle. End diastolic (ED) and end systolic (ES) phase
were determined by the software and cardiac function
parameters (ED and ES mass, EDV, ESV and EF) were
calculated automatically. Ventricular mass is deﬁned as
the average of the ED and ES mass. As an internal control,
a maximum mass diﬀerence of 10% was accepted. This was
achieved for all mice. End diastolic volume (EDV) and end
systolic volume (ESV) were determined, and stroke volume
(SV = EDVESV), ejection fraction (EF = (SV/EDV) 
100%) and cardiac output (CO = SV  heart rate) were
calculated from these parameters.
2.4. Statistical analysis
Data are represented as mean ± SD. Statistical analyses
were performed using SPSS 17.0.2 (SPSS, Inc., Chicago,
IL, USA). Statistical signiﬁcance between all four groups
at 2 months was assessed using one-way analysis of vari-
ance (ANOVA), followed by a Bonferroni correction for
multiple testing in case of signiﬁcance (P < 0.05). C57Bl/
10ScSnJ, mdx (C57Bl/10ScSn-DMDmdx/J), and mdx/
utrn+/ mice were compared over time with two-way
ANOVA, followed by a LSD correction for multiple test-
ing, in case of signiﬁcance (P < 0.05).A
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Fig. 1. Left ventricular function of 2 months old mdx and mdx/utrn+/ mice is
Per group 6 mice (3 male and 3 female) were analysed at the age of 2 mont
deviation. (A) Ejection fraction. (B) Cardiac output: a large decrease was seen
mdx/utrn/ mice showed a severe decline in SV, which was not seen in other g
mice, which is only signiﬁcant compared to mdx utrn+/ mice. *P < 0.05, **P2.5. Histology
Sections of 8 lm were cut with a Shandon cryotome
(Thermo Fisher Scientiﬁc Co., Pittsburgh, PA, USA)
on Superfrost Plus slides (Thermo Fisher Scientiﬁc, Men-
zel-Gla¨ser, Germany) along the entire length of the heart
with a minimum interval of 240 lm between the sections.
Slides were ﬁxed for 5 min in ice-cold acetone and
stained using the Masson’s Trichrome staining (Sigma–
Aldrich, The Netherlands). Pictures were taken at 2.5
magniﬁcation with a Leica DC500 camera and Leica
IM50 software connected to a Leica DM LB light micro-
scope (Leica Microsystems, The Netherlands). For blend-
ing and background correction Adobe Photoshop CS3
version 10.0.1 was used.
3. Results
3.1. Cardiac function is impaired in 2 months old
mdx/utrn/ mice
Heart function of all mice strains was determined at the
age of 2 months. At this time point, no diﬀerences in ven-
tricular function were found between mdx, mdx/utrn+/
and wild-type (C57Bl/10ScSnJ) mice (Fig. 1). In contrast,
mdx/utrn/ mice showed clear signs of cardiomyopathy.
Left ventricular function was diminished as reﬂected by a
signiﬁcant decrease in cardiac output (CO), stroke volume
(SV) and end diastolic volume (EDV), while no diﬀerence
was observed for the ejection fraction (EF).B
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comparable to wild-type mice, but severely impaired in mdx/utrn/ mice.
hs. Means are shown for each group. Error bars represent the standard
in mdx/utrn/ mice compared to all other genotypes. (C) Stroke volume:
enotypes. (D) End diastolic volume: a mild decrease is seen in mdx/utrn/
< 0.01.
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marked (Fig. 2), with only the EF showing a signiﬁcant
decrease in comparison with all other mouse strains.3.2. Cardiac function declines in mdx and mdx/utrn+/ mice
during ageing
For wild-type, mdx and mdx/utrn+/ mice, heart func-
tion was also determined at 6 and 10 months of age.
Wild-type mice showed a stable heart function during age-
ing for both the left and the right ventricle (Figs. 3 and 4).
In contrast, the mdx and mdx/utrn+/ mice showed a dete-
rioration of the left ventricular function with age. Whereas
at 2 and 6 months the heart function was still comparable
to that of wild-type mice, a decrease in SV was seen at
the age of 10 month, which was signiﬁcant in mdx mice,
but not in mdx/utrn+/ mice due to larger interindividual
variation. Cardiac output, as computed by stroke volume
times heart rate, was not decreased, which might by
explained by a compensatory increase in heart rate in the
mdx/utrn+/ mice (Fig. 5).
The ageing eﬀect was much more pronounced in the
right ventricle (Fig. 4). While right ventricular function
was stable over time in wild-type mice, a small decrease
was already visible at the age of 6 months in mdx and
mdx/utrn+/ mice, which became more prominent at
10 months of age. For both mdx and mdx/utrn+/ mice
the EF started to decline at 6 months and was markedly
decreased at 10 months of age. The CO remained stable
over time in wild-type mice, but a trend towards a declineA
C
Ejection fraction RV at 2 months
0
20
40
60
80
Wild-type mdx mdx utrn +/- mdx utrn -/-
Wild-type mdx mdx utrn +/- mdx utrn -/-
EF
 (%
)
**
Stroke volume RV at 2 months
0
5
10
15
20
25
SV
 (µ
L)
Fig. 2. Right ventricular function 2 months old mdx and mdx/utrn+/mice is co
6 mice (3 male and 3 female) were analysed at the age of 2 months. Means ar
Ejection fraction: EF was severely impaired in mdx/utrn/ mice compared t
Cardiac output: a mild but not signiﬁcant decrease was seen in mdx/utrn/mic
this was not signiﬁcant. (D) End diastolic volume: due to large variations betat 10 months was seen. In both mdx and mdx/utrn+/ a sig-
niﬁcant lowering of SV compared to wild-type mice was
seen, which mainly seemed to be at the age of 10 months.
In the EDV no diﬀerences were observed.
The impairment in heart function as seen in mdx and
mdx/utrn+/ mice correlated with the formation of ﬁbrotic
tissue in these mice during ageing (Fig. 6). Whereas mini-
mal amounts of ﬁbrosis were seen in both young and older
wild-type mice, ﬁbrotic areas are prominent in 10 months
old mdx mice. Mdx/utrn+/ mice already showed some
ﬁbrotic tissue at 2 months of age and this was clearly visible
in mice of both 6 and 10 months of age.4. Discussion
The majority of DMD patients exhibits a decline in car-
diac function, starting around the age of 10 and gradually
worsening during disease progression. Currently, several
therapies for DMD are under development. Most promi-
nent are antisense oligonucleotides (AONs) which aim to
skip the targeted exon to correct the disrupted reading
frame in DMD [10,28–30]. However, the AONs currently
tested in clinical trials lead to exon skipping in skeletal
muscle, but hardly in the heart [31]. Because AONs are
not yet very eﬀective in the heart, cardiac problems may
become a more prominent and disabling aspect of the dis-
ease for patients treated with AONs (should exon skipping
become clinically available). In addition, due to improve-
ments in health care, the life expectancy of DMD patients
is increasing and cardiac problems become more and moreCardiac output RV at 2 months
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Fig. 3. Left ventricular functions showed mild impairment in ageing mdx and mdx/utrn+/ mice, but not in wild-type mice. Per time point (2, 6 and
10 months) 6 mice (3 male and 3 female) of each genotype were analysed. Means are shown for each group. Error bars represent the standard deviation.
(A) Ejection fraction: in wild-type mice EF is stable over time. Mdx mice showed a signiﬁcant decrease at 10 months compared to 2 months, but due to
variation this was not signiﬁcant compared to age-matched wild-type mice. (B) Cardiac output: no diﬀerences were observed between all genotypes and age
groups. (C) Stroke volume: both mdx and mdx/utrn+/ mice, but not wild-type mice, showed a decrease in SV at the age of 10 months, but due to
individual diﬀerences this was only signiﬁcant in mdx mice. (D) End diastolic volume: no diﬀerences were observed between all genotypes at all ages.
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has shown that rescue of the diaphragm function might
be enough to rescue also heart function [32]. Nevertheless
the (partial) rescue of skeletal function by the exon skiptherapy might cause the patients to become more active,
thereby increasing the workload on the heart, as has been
observed in animal models with a microdystrophin trans-
gene [33]. Therefore potential therapies should not only
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Fig. 5. Heart rate was stable in ageing wild-type mice, but increased in
aged mdx and mdx/utrn+/ mice. At 2 months of age no diﬀerences in
heart rate were observed, but at the age of 10 months heart rate was
increased in mdx and mdx/utrn+/ mice compared to wild-type. *P < 0.05.
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eﬀect of these therapies on the heart a basic understanding
of the heart function of the used models is necessary.
Previous studies have shown that, although global heart
function appears normal as assessed by global methods
(e.g. conventional ECG), more sensitive methods can
detect cardiac changes in early stages of the disease. InWild-type
2 months 6
Mdx
Mdx utrn+/-
Mdx utrn -/-
Fig. 6. Fibrosis is clearly visible in aged mdx and mdx/utrn+/ mice, whereas w
mice showed minimal amounts of ﬁbrosis at the age of ten months, clear ﬁbro
already became visible in mdx/utrn+/ mice at the age of 2 and 6 months. Als
lesser extend as mdx/utrn+/ mice. The immobility of the animals might play a
Representative examples are shown for each group.mdx mice cardiovascular magnetic resonance (CMR) tag-
ging revealed functional alterations (a decrease in myocar-
dial wall strain and torsion) in 10 months old mice [20]. In
25 weeks old GRMD dogs a decrease in function (decrease
in myocardial velocity gradient) tissue Doppler imaging
(TDI), despite normal ECGs [34]. Also in humans TDI
has been able to detect alterations while conventional echo-
cardiograms remained normal [35]. This indicates more
sensitive methods are needed to detect cardiomyopathy
early and follow while ageing. MRI is a widely used tech-
nique to study heart function with high resolution in both
humans and animals. In this study we showed it can be
used to follow the development of cardiac decline in diﬀer-
ent mouse models for DMD.
The mdx/utrn/ mouse is the most severely aﬀected
mouse model. These mice have a life expectancy of approx-
imately 8–10 weeks and by that time clear impairment of
muscle function is seen. These mice have been not yet been
well characterised with respect to cardiac involvement.
Using histological analysis, some studies found minimal
amounts of ﬁbrosis and necrosis around the age of
10 weeks in the mdx/utrn/ model, and no signs of dilated
cardiomyopathy, comparable to age-matched mdx mice,
[13] whereas others did ﬁnd inﬂammation, cardiomyocyte months 10 months
ild-type mice show minimal ﬁbrotic tissue at the same age. While wild-type
tic areas (blue) were visible mdx and mdx/utrn+/ mice at this age. These
o 2 months old mdx/utrn/ mice show some ﬁbrotic areas, although to a
role in the relatively little formation of ﬁbrosis in the mdx/utrn/ mice.
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of the same age [36]. However ECGs of 2 months old mdx/
utrn/ mice were abnormal (decrease in S/R wave ratio)
[16]. Furthermore contractile dysfunction of right ventricu-
lar muscles was worse in mdx/utrn/ mice than in mdx
mice [37]. The severe scoliosis of these mice has an eﬀect
on the anatomical position of the heart and thereby ham-
pers the electrophysiological monitoring of cardiac func-
tion by ECG. However, with MRI it is possible to
reliably quantify cardiac volumes and function without
geometrical assumptions in these mice. Analysis clearly
revealed that the skeletal muscle impairment was also
reﬂected by a large decrease in cardiac function of both
the left and the right ventricle. In the left ventricle a decline
in stroke volume was observed. Patient-studies have shown
the same pattern: heart failure with a preserved ejection
fraction, probably due to left ventricular hypertrophy
and increased muscle mass [38]. There was also a decrease
in EDV, whereas an increase is expected if cardiac function
declines. This can be explained by the cardiac mass of the
left ventricle, which was also signiﬁcantly lower in the
mdx/utrn/ mice compared to all other genotypes. The
decrease in right ventricular function was less marked. This
might be due to the severe respiratory problems seen in
these mice, which results in a relatively lower workload
on the right ventricle compared to the left ventricle, since
the left ventricle must compensate for the decreased oxygen
supply. Furthermore there is a large phenotypical variation
between individual mice.
In addition to impairment of skeletal muscle function,
the mdx mouse model also presents with heart failure.
There have been some studies which assessed heart func-
tion in mdx mice. ECG abnormalities have been found at
the age of 6 months. They showed a decreased S/R wave
ratio compared to control mice [16]. These changes are sim-
ilar to those found in the ECGs of the majority of DMD
patients [39]. Left ventricular dysfunction (dilated cardio-
myopathy) was seen in older mdx mice. At the age of 6–
8 months, mild changes (decreased ejection fraction (EF)
and cardiac output (CO)) were found, which became more
prominent from the age of around 9–10 months
[17,18,32,40]. Furthermore mdx mice of this age showed a
large increase in interstitional ﬁbrosis compared to wild-
type mice [18]. Right ventricular dysfunction seems to pre-
cede left ventricular dysfunction, as there was a clear
decrease in EF and CO already at the age of 6 months
[32]. Our ﬁndings support these ﬁndings, as we report that
whereas wild-type mice have stable heart function during
ageing, mdx mice showed a clear cardiomyopathy at the
age of 10 months. In the left ventricle this was reﬂected
by a decrease in stroke volume. The stroke volume (SV)
is the diﬀerence between the end diastolic volume (EDV)
and the end systolic volume (ESV), whereas the ejection
fraction (EF) is both dependent on the EDV and the SV.
This might be an explanation why diﬀerences in one
parameter are not always reﬂected in the other parameters.
Cardiac output (CO) is dependent on the heart rate of themice. Although a decrease of SV in aged mdx and mdx/
utrn+/ mice was observed, this was not accompanied by
a decrease in CO. The increase in heart rate observed in
these mice, might be a reason for this, as a compensatory
mechanism for the decrease in SV. This must be said with
some precaution, since the mice were anaesthetized. How-
ever, previous studies showed that isoﬂurane anaesthesia
has a large inﬂuence respiration rate, but heart function
as measured with cine-MRI was independent of anaesthe-
sia depth [34]. Whereas small indications of cardiomyopa-
thy were seen in the left ventricle, it was marked in the right
ventricle as was reﬂected by a signiﬁcant decline or a trend
towards a functional decrease in almost all functional
parameters. This is compatible with previous studies, which
showed an earlier and more pronounced functional decline
of the right ventricle compared with the left ventricle
[17,18,32,40].
A small limitation of the study is the observation that
the determined CO in the right ventricle is smaller than
in the left ventricle in all mice. This is not a true diﬀerence,
but the result of the more complex and irregular shape of
the right ventricle. As a result, the right ventricle is not
sampled perpendicularly to the ventricular wall in every
slice using short-axis cine MRI, thereby underestimating
the ventricle dimensions. Secondly, diﬀerentiation of the
pulmonary and the tricuspid valves is diﬃcult, resulting
in larger analysis errors for right ventricle when compared
to left ventricular measurements [41]. However, since this
diﬀerence is similar for all mice (regardless of genotype,
age group or gender) and all mice are analysed in the same
way, this limitation does not aﬀect the comparability
between the diﬀerent groups in this study.
A good comparison over time between diﬀerent mouse
models with varying levels of utrophin has not been done.
We found the same pattern in mdx/utrn+/ mice as for mdx
mice, i.e. a mild decrease in left ventricular function and a
large decrease in right ventricular function at the age of
10 months. Surprisingly, although the skeletal function of
these mice is more aﬀected than that of mdxmice, (van Put-
ten et al., unpublished observations) this was not seen in
cardiac function. Furthermore the variation between indi-
vidual mdx/utrn+/ mice was large. This is probably due
to the heterogeneity in background of these mice [15].
The functional decline in mdx and mdx/utrn+/ mice as
was seen by MRI analysis, correlated with the amount of
ﬁbrosis seen in mice of the diﬀerent genotypes and ages.
Although it was increased compared to age matched mdx
and wild-type mice, there seemed to be less ﬁbrosis in
mdx/utrn/ mice compared mdx/utrn+/ mice of the same
age. This might be due to the severe phenotype of the ani-
mals, which causes immobility and thereby less activity of
the heart.
The cardiomyopathy observed in the diﬀerent DMD
mouse models shows resemblance to DMD patients, but
some discrepancies are also seen. Whereas in humans
mainly the left ventricle is involved, in mice the eﬀects are
more pronounced in the right ventricle [7]. A possible
I.E.C. Verhaart et al. / Neuromuscular Disorders 22 (2012) 418–426 425explanation is the diﬀerences in underlying respiratory
pathology in mice and humans. When humans develop
respiratory problems, assisted ventilation is started,
whereas in mice respiratory failure is not treated. A recent
study has shown that in mice respiratory intervention had a
beneﬁcial eﬀect on heart function too [32].
In conclusion we have shown that MRI is a reliable tool
to study heart function in dystrophinopathy mouse models
and these mouse models exhibit a decline in cardiac func-
tion correlated with disease progression. Therefore these
mice are a versatile tool to study the eﬀect of potential ther-
apies, like AON mediated exon skipping, on the heart, in
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